Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
| Status: | Completed |
|---|---|
| Conditions: | Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 10/7/2017 |
| Start Date: | September 2007 |
| End Date: | February 2009 |
A Pilot Study Evaluating the Effect of Pioglitazone, Simvastatin, and Ibuprofen on Neutrophil Migration in Vivo in Healthy Subjects
Inflammation clearly contributes to the progression of the cystic fibrosis (CF) lung disease,
and administration of the anti-inflammatory agent high-dose ibuprofen retards the rate of
decline of pulmonary function. However, utilization of this valuable drug has been suboptimal
because of its rare, but dramatic, adverse effects. Therefore, alternative anti-inflammatory
agents are urgently needed. One strategy for identifying new anti-inflammatory agents is to
determine the mechanism by which the only proven anti-inflammatory agent for the CF lung
disease, high-dose ibuprofen, exerts its effect. If this were known, then other drugs that
act by a similar mechanism become candidates for treating the CF inflammatory disease. The
investigators have shown, in our preliminary studies, that high dose ibuprofen limits the
delivery of neutrophils to an inflamed mucosal surface, the gingival crevices. The
investigators plan to test pioglitazone and simvastatin, (ibuprofen (positive control)) to
determine their anti inflammatory affects on neutrophil migration to the oral mucosa.
The hypothesis to be tested is that pioglitazone, and/or simvastatin will reduce neutrophils
in the oral mucosa after 10 days of therapy in mouthwashes of healthy volunteers. Ibuprofen
will be used as a positive control.
This study will provide pilot data from healthy volunteers to support an FDA Grant to be
submitted at a future date.
and administration of the anti-inflammatory agent high-dose ibuprofen retards the rate of
decline of pulmonary function. However, utilization of this valuable drug has been suboptimal
because of its rare, but dramatic, adverse effects. Therefore, alternative anti-inflammatory
agents are urgently needed. One strategy for identifying new anti-inflammatory agents is to
determine the mechanism by which the only proven anti-inflammatory agent for the CF lung
disease, high-dose ibuprofen, exerts its effect. If this were known, then other drugs that
act by a similar mechanism become candidates for treating the CF inflammatory disease. The
investigators have shown, in our preliminary studies, that high dose ibuprofen limits the
delivery of neutrophils to an inflamed mucosal surface, the gingival crevices. The
investigators plan to test pioglitazone and simvastatin, (ibuprofen (positive control)) to
determine their anti inflammatory affects on neutrophil migration to the oral mucosa.
The hypothesis to be tested is that pioglitazone, and/or simvastatin will reduce neutrophils
in the oral mucosa after 10 days of therapy in mouthwashes of healthy volunteers. Ibuprofen
will be used as a positive control.
This study will provide pilot data from healthy volunteers to support an FDA Grant to be
submitted at a future date.
The entire study period for each subject will be 15 days, and consist of 3 periods defined
as: Baseline (Day 1,2,3), Treatment (Day 3-10), and Recovery (Day 13-15). Healthy volunteers
will be screened on Day 1 (and assessed for eligibility); Eligible subjects will be divided
into 3 drug treatment groups pioglitazone, simvastatin and ibuprofen the positive control.
The two treatment groups will consist of 4 healthy volunteers who meet the inclusion
criteria. There will be 2 healthy volunteers in the positive control group. Group 1 will
receive pioglitazone 30 mg once daily, Group 2 will receive simvastatin 40 mg daily and Group
3 the positive control will receive ibuprofen (15-23 mg/kg twice daily, maximum 3200 mg/day)
during the Treatment period and serve as the positive control group. This dose is 25% of that
prescribed to CF patients. As healthy volunteers are recruited, the first will be assigned to
Group 1, the second to Group 2, and so on. After the third subject has been assigned to Group
3, this pattern of assignment will be repeated with subjects 4, 5 and 6, The following 4
healthy volunteers will be assigned to group 1 and 2 (7, 8, 9, 10).
as: Baseline (Day 1,2,3), Treatment (Day 3-10), and Recovery (Day 13-15). Healthy volunteers
will be screened on Day 1 (and assessed for eligibility); Eligible subjects will be divided
into 3 drug treatment groups pioglitazone, simvastatin and ibuprofen the positive control.
The two treatment groups will consist of 4 healthy volunteers who meet the inclusion
criteria. There will be 2 healthy volunteers in the positive control group. Group 1 will
receive pioglitazone 30 mg once daily, Group 2 will receive simvastatin 40 mg daily and Group
3 the positive control will receive ibuprofen (15-23 mg/kg twice daily, maximum 3200 mg/day)
during the Treatment period and serve as the positive control group. This dose is 25% of that
prescribed to CF patients. As healthy volunteers are recruited, the first will be assigned to
Group 1, the second to Group 2, and so on. After the third subject has been assigned to Group
3, this pattern of assignment will be repeated with subjects 4, 5 and 6, The following 4
healthy volunteers will be assigned to group 1 and 2 (7, 8, 9, 10).
Inclusion Criteria:
- ≥ 18 < 50 years of age
- Healthy volunteers must be in general good health as determined by a medical history.
- Ability to understand and sign the informed consent form
- Ability to adhere to the protocol.
- Willing to use an acceptable form of birth control
Exclusion Criteria:
- History of diabetes requiring insulin
- The use of NSAIDS (ibuprofen) or corticosteroids including inhaled steroids. Nasal
steroids are acceptable.
- The use of statin lowering medications
- Active gingival disease (Active tooth or gum disease)
- Any chronic inflammatory condition that immuno compromises the volunteer as determined
by medical history.
- Pregnant or planning to become pregnant
We found this trial at
2
sites
Rainbow Babies and Children's Hospital UH Rainbow Babies & Children’s Hospital is a 244-bed, full-service...
Click here to add this to my saved trials
University Hospitals of Cleveland The history of University Hospitals Case Medical Center is linked to...
Click here to add this to my saved trials